Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia.

Abstract:

OBJECTIVE:Glucocorticoids are used universally in the remission induction therapy for acute lymphoblastic leukemia (ALL). One of the adverse effects of glucocorticoids is hypertension. Our aim was to define the frequency of and clinical and genetic risk factors for steroid-induced hypertension. METHODS:We determined the genotypes for 203 candidate polymorphisms in genes previously linked to hypertension or to the pharmacokinetics or pharmacodynamics of antileukemic agents. Hypertension was defined according to the guidelines of the American Academy of Pediatrics; patients were evaluated during the 28-day period of prednisone at 40 mg/m2/day during remission induction of childhood ALL. RESULTS:Of the 602 children with newly diagnosed ALL who were normotensive pretherapy, 270 (45%) developed hypertension during remission induction. None of the putative risk factors (age, sex, race, white blood cell count, risk group, body mass index, or serum creatinine) was associated with hypertension. Among the polymorphisms genotyped, we identified eight genes (CNTNAP2, LEPR, CRHR1, NTAN1, SLC12A3, ALPL, BGLAP, and APOB) containing variants that were associated with hypertension (chi2 P values 0.002-0.048), several of which interact with the hypothalamus-pituitary-adrenal axis. Polymorphisms in CYP3A4 and CYP3A5 were not associated with hypertension. CONCLUSION:Hypertension is common during ALL remission induction and is related to germline genetic variation.

journal_name

Pharmacogenet Genomics

authors

Kamdem LK,Hamilton L,Cheng C,Liu W,Yang W,Johnson JA,Pui CH,Relling MV

doi

10.1097/FPC.0b013e3282fc5801

subject

Has Abstract

pub_date

2008-06-01 00:00:00

pages

507-14

issue

6

eissn

1744-6872

issn

1744-6880

journal_volume

18

pub_type

杂志文章
  • Meta-analysis and systematic review of the effect of the donor and recipient CYP3A5 6986A>G genotype on tacrolimus dose requirements in liver transplantation.

    abstract:OBJECTIVE:A meta-analysis was carried out of published studies on the effect of the CYP3A5 6986A>G polymorphism in liver donors and transplant recipients on tacrolimus pharmacokinetics. METHODS:Cohort studies that evaluated the relationship between the CYP3A5 polymorphism in liver donors and transplant recipients and ...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章,meta分析,评审

    doi:10.1097/FPC.0b013e3283642fb3

    authors: Rojas LE,Herrero MJ,Bosó V,García-Eliz M,Poveda JL,Librero J,Aliño SF

    更新日期:2013-10-01 00:00:00

  • The hemodynamic response to constant dobutamine infusion: the effect of ADRB1 389 polymorphism and sex.

    abstract:OBJECTIVES:Prolonged activation of the β-1 adrenergic receptor (ADRB1) is associated with receptor desensitization. This process has been suggested to have important pathophysiological and clinical implications in conditions such as congestive heart failure. The contribution of genetic factors to this process is a subj...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000338

    authors: Yogev D,Basheer M,Perlman A,Blotnick S,Caraco Y,Muszkat M

    更新日期:2018-06-01 00:00:00

  • Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding.

    abstract:OBJECTIVES:To analyze whether gene variants leading to impaired drug metabolism are related with acute gastrointestinal bleeding after nonsteroidal anti-inflammatory drugs (NSAID) use. METHODS:Common CYP2C8 and CYP2C9 polymorphisms were studied in a cross-sectional study, involving 134 NSAID-related bleeding patients ...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e3282f305a9

    authors: Blanco G,Martínez C,Ladero JM,Garcia-Martin E,Taxonera C,Gamito FG,Diaz-Rubio M,Agundez JA

    更新日期:2008-01-01 00:00:00

  • Pharmacogenetic effects of 'candidate gene complexes' on stroke in the GenHAT study.

    abstract:OBJECTIVE:The aim of this study was to investigate whether there is a genotype-by-treatment interaction in patients experiencing stroke and treated with one of three antihypertensive drugs, that is chlorthalidone, amlodipine, or lisinopril. PARTICIPANTS AND METHODS:A population of 436 African Americans and 539 whites ...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000088

    authors: Sørensen IF,Vazquez AI,Irvin MR,Sørensen P,Davis BR,Ford CE,Boerwinkle E,Eckfeldt JH,Arnett DK

    更新日期:2014-11-01 00:00:00

  • A candidate-gene association study of topiramate-induced weight loss in obese patients with and without type 2 diabetes mellitus.

    abstract:OBJECTIVE:Clinical response to topiramate can vary greatly in obese patients. Identifying genetic variants associated with treatment response could help gain insight into the mechanism of action of topiramate. Little is known about the relationship between genetic variability and topiramate treatment response. We perfo...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000185

    authors: Li QS,Lenhard JM,Zhan Y,Konvicka K,Athanasiou MC,Strauss RS,Francke S

    更新日期:2016-02-01 00:00:00

  • Common genetic variation in six lipid-related and statin-related genes, statin use and risk of incident nonfatal myocardial infarction and stroke.

    abstract:OBJECTIVE:Genetic polymorphisms are associated with lipid-lowering response to statins, but generalizeability to disease endpoints is unclear. The association between 82 common single nucleotide polymorphisms (SNPs) in six lipid-related or statin-related genes (ABCB1, CETP, HMGCR, LDLR, LIPC, NOS3) and incident nonfata...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e3283033528

    authors: Hindorff LA,Lemaitre RN,Smith NL,Bis JC,Marciante KD,Rice KM,Lumley T,Enquobahrie DA,Li G,Heckbert SR,Psaty BM

    更新日期:2008-08-01 00:00:00

  • Multidrug resistance-related protein 2 genotype of the donor affects kidney graft function.

    abstract:OBJECTIVES:We tested the effect of kidney-specific multidrug resistance-related protein (MRP2, ABCC2) deficiency on renal organic solute disposition as well as on renal protein and gene expression. Furthermore, we investigated whether a particular kidney donor ABCC2 genotype is associated with delayed graft function in...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e328328d4e9

    authors: Grisk O,Steinbach AC,Ciecholewski S,Schlüter T,Klöting I,Schmidt H,Dazert E,Schaeffeler E,Steil L,Gauer S,Jedlitschky G,Schwab M,Geisslinger G,Hauser IA,Völker U,Kroemer HK,Rettig R

    更新日期:2009-04-01 00:00:00

  • Three haplotypes associated with CYP2A6 phenotypes in Caucasians.

    abstract::The human cytochrome P450 2A6 (CYP2A6) enzyme metabolizes several xenobiotic compounds of clinical or toxicological importance. We aimed to identify genetic variants and major CYP2A6 haplotypes associated with CYP2A6 phenotypic variation. CYP2A6 mRNA level, protein level, activity and haplotypes were determined in Cau...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/01.fpc.0000171517.22258.f1

    authors: Haberl M,Anwald B,Klein K,Weil R,Fuss C,Gepdiremen A,Zanger UM,Meyer UA,Wojnowski L

    更新日期:2005-09-01 00:00:00

  • Variants in COMT and spontaneous smoking cessation: retrospective cohort analysis of 925 cessation events.

    abstract::Genome-wide studies have identified single nucleotide polymorphisms associated with smoking behaviour and nicotine dependence. Less is known about genetic determinants of smoking cessation, but rs4680 in COMT has recently been shown to explain a substantial proportion of the variation in cessation in the general popul...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e32832fabf3

    authors: Breitling LP,Dahmen N,Illig T,Rujescu D,Nitz B,Raum E,Winterer G,Rothenbacher D,Brenner H

    更新日期:2009-08-01 00:00:00

  • The role of genetic polymorphisms in the thymidylate synthase (TYMS) gene in methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia.

    abstract:OBJECTIVE:Methotrexate (MTX) is an important drug in the treatment of pediatric acute lymphoblastic leukemia (ALL). MTX is cytotoxic as it impairs DNA and RNA synthesis by inhibiting the enzymes dihydrofolate reductase (DHFR) and thymidylate synthase (TYMS). The association between genetic variants within the TYMS gene...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章,meta分析

    doi:10.1097/FPC.0000000000000352

    authors: Oosterom N,Berrevoets M,den Hoed MAH,Zolk O,Hoerning S,Pluijm SMF,Pieters R,de Jonge R,Tissing WJE,van den Heuvel-Eibrink MM,Heil SG

    更新日期:2018-10-01 00:00:00

  • Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine.

    abstract:OBJECTIVES:The effect of rifapentine plus isoniazid on efavirenz pharmacokinetics was characterized in AIDS Clinical Trials Group protocol A5279 (NCT01404312). The present analyses characterize pharmacogenetic interactions between these drugs, and with nevirapine. METHODS:A subset of HIV-positive individuals receiving...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000417

    authors: Haas DW,Podany AT,Bao Y,Swindells S,Chaisson RE,Mwelase N,Supparatpinyo K,Mohapi L,Gupta A,Benson CA,Baker P,Fletcher CV

    更新日期:2021-01-01 00:00:00

  • Strongly increased exposure of meloxicam in CYP2C9*3/*3 individuals.

    abstract:OBJECTIVE:The effects of CYP2C9*1/*3 and *3/*3 genotypes on the pharmacokinetics and pharmacodynamics of meloxicam were evaluated in healthy Korean subjects. METHODS:After oral administration of 15 mg meloxicam, the plasma concentrations of meloxicam were assessed in 11 CYP2C9*1/*1 individuals, eight CYP2C9*1/*3 indiv...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000025

    authors: Lee HI,Bae JW,Choi CI,Lee YJ,Byeon JY,Jang CG,Lee SY

    更新日期:2014-02-01 00:00:00

  • The influence of the CYP2C19*10 allele on clopidogrel activation and CYP2C19*2 genotyping.

    abstract:BACKGROUND/OBJECTIVES:The polymorphic hepatic enzyme CYP2C19 catalyzes the metabolism of clinically important drugs such as clopidogrel, proton-pump inhibitors, and others and clinical pharmacogenetic testing for clopidogrel is increasingly common. The CYP2C19*10 single-nucleotide polymorphism (SNP) is located 1 bp ups...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000068

    authors: Langaee TY,Zhu HJ,Wang X,El Rouby N,Markowitz JS,Goldstein JA,Johnson JA

    更新日期:2014-08-01 00:00:00

  • Genetic polymorphisms in TP53, nonsteroidal anti-inflammatory drugs and the risk of colorectal cancer: evidence for gene-environment interaction?

    abstract:OBJECTIVE:Substantial evidence indicates that nonsteroidal anti-inflammatory drugs protect against colorectal cancer by altering cell cycle progression and/or inducing apoptosis, whereas p53 protein is crucial to maintaining cell-cycle arrest and regulating DNA repair, differentiation, and apoptosis. Genetic variants i...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e3280d5121c

    authors: Tan XL,Nieters A,Hoffmeister M,Beckmann L,Brenner H,Chang-Claude J

    更新日期:2007-08-01 00:00:00

  • The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation.

    abstract:OBJECTIVE:The prototypical atypical antipsychotic agent, clozapine, is more efficacious for refractory schizophrenia than the 'typical' antipsychotics, but the mechanism underlying this enhanced efficacy is still under investigation. Since 2002, at least 22 association studies have shown that the DTNBP1 can be associat...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/FPC.0b013e32832b9cfc

    authors: Zuo L,Luo X,Krystal JH,Cramer J,Charney DS,Gelernter J

    更新日期:2009-06-01 00:00:00

  • A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation.

    abstract:OBJECTIVE:The objective of the present study was to evaluate whether germline methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms as well as polymorphisms in the thymidylate synthase gene promoter, namely the variable number tandem repeat polymorphism (TS VNTR) and the intrarepeat G to C single n...

    journal_title:Pharmacogenetics and genomics

    pub_type: 临床试验,杂志文章

    doi:10.1097/01.fpc.0000230412.89973.c0

    authors: Terrazzino S,Agostini M,Pucciarelli S,Pasetto LM,Friso ML,Ambrosi A,Lisi V,Leon A,Lise M,Nitti D

    更新日期:2006-11-01 00:00:00

  • COMT gene and risk for Parkinson's disease: a systematic review and meta-analysis.

    abstract:BACKGROUND/AIMS:Several single-nucleotide polymorphisms (SNPs) in the catechol-O-methyltransferase (COMT) gene have been associated with the risk of developing Parkinson's disease (PD). We conducted a systematic review and a meta-analysis including all the studies published on PD risk related with COMT SNPs (mainly rs4...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章,meta分析,评审

    doi:10.1097/FPC.0000000000000056

    authors: Jiménez-Jiménez FJ,Alonso-Navarro H,García-Martín E,Agúndez JA

    更新日期:2014-07-01 00:00:00

  • Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid.

    abstract:OBJECTIVE:The effects of various polymorphisms in cytochrome P450 (CYP) enzyme and transporter genes on the pharmacokinetics (PK) of simvastatin were evaluated in healthy Korean men. METHODS:Plasma concentration data for simvastatin and simvastatin acid were pooled from four phase I studies comprising 133 participants...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/FPC.0000000000000176

    authors: Choi HY,Bae KS,Cho SH,Ghim JL,Choe S,Jung JA,Jin SJ,Kim HS,Lim HS

    更新日期:2015-12-01 00:00:00

  • Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients.

    abstract:OBJECTIVE:The immunosuppressive drug tacrolimus requires strict therapeutic monitoring due to its narrow therapeutic index and great inter-individual variability. Cytochrome P450 3A4 (Cyp3A4) and Cyp3A5 are the most important contributors to tacrolimus metabolism while the P-glycoprotein pump (MDR-1) modulates its bioa...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/01.fpc.0000220571.20961.dd

    authors: Roy JN,Barama A,Poirier C,Vinet B,Roger M

    更新日期:2006-09-01 00:00:00

  • Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia.

    abstract::Several novel single nucleotide polymorphisms (SNPs) involved in cytarabine cytotoxicity and related to clinical outcomes have been reported recently in a series of 232 pediatric patients with acute myeloid leukemia (AML). We report the first adult AML cohort in which the influence of these SNPs in cytarabine efficacy...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000286

    authors: Megías-Vericat JE,Montesinos P,Herrero MJ,Moscardó F,Bosó V,Martínez-Cuadrón D,Poveda JL,Sanz MÁ,Aliño SF

    更新日期:2017-07-01 00:00:00

  • Study of the genetic determinants of UGT1A1 inducibility by phenobarbital in cultured human hepatocytes.

    abstract::UGT1A1 is induced by phenobarbital. We investigated whether three common UGT1A1 variants are associated with the variability in UGT1A1 inducibility. Human hepatocytes were incubated with 2 mM phenobarbital for 2 and 6 days followed by 5 microM SN-38 (1 h), a UGT1A1 probe. SN-38 glucuronidation in the cell media was me...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/01.fpc.0000182784.77630.48

    authors: Ramírez J,Komoroski BJ,Mirkov S,Graber AY,Fackenthal DL,Schuetz EG,Das S,Ratain MJ,Innocenti F,Strom SC

    更新日期:2006-02-01 00:00:00

  • Deciphering ADME genetic data using an automated haplotype approach.

    abstract:OBJECTIVE:To investigate the utility of statistical tools in translating Affymetrix Drug Metabolizing Enzyme and Transporter (DMET) Assay single-nucleotide polymorphisms (SNPs) into common consensus star alleles. METHODS:DMET SNP data from clinical trials in different ethnicities were pooled for analyses. Three differ...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000047

    authors: Guo Y,Farmen MW,Jin Y,Lee HY,Penny MA,Hillgren KM,Fossceco SL

    更新日期:2014-06-01 00:00:00

  • Large-scale candidate gene study to identify genetic risk factors predictive of paliperidone treatment response in patients with schizophrenia.

    abstract:OBJECTIVE:Clinical response to antipsychotic medications can vary markedly in patients with schizophrenia. Identifying genetic variants associated with treatment response could help optimize patient care and outcome. To this end, we carried out a large-scale candidate gene study to identify genetic risk factors predict...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000122

    authors: Wang D,Fu DJ,Wu X,Shapiro A,Favis R,Savitz A,Chung H,Alphs L,Gopal S,Haas M,Cohen N,Li Q

    更新日期:2015-04-01 00:00:00

  • Association of the UGT1A1-53(TA)n polymorphism with L-thyroxine doses required for thyrotropin suppression in patients with differentiated thyroid cancer.

    abstract::There is a considerable interindividual variation in L-thyroxine [3,5,3',5'-tetraiodo-l-thyronine (T4)] dose required for thyrotropin (thyroid-stimulating hormone) suppression in patients with differentiated thyroid cancer. To investigate whether uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)-mediated T4 gl...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e3283448d19

    authors: Vargens DD,Neves RR,Bulzico DA,Ojopi EB,Meirelles RM,Pessoa CN,Prado CM,Gonçalves PA,Leal VL,Suarez-Kurtz G

    更新日期:2011-06-01 00:00:00

  • The relevance of the individual screening for genetic variants in predicting ovarian response.

    abstract:OBJECTIVE:To investigate if polymorphisms of some genes involved in folliculogenesis predict ovarian response. METHODS:This prospective randomized study includes 124 egg donors genotyped for six SNPs ESR1 (rs2234693), AMHR2 (rs2002555), GDF-9 (rs10491279 and rs254286), AMH (rs10407022) and LHCBR (rs229327) genes and f...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000386

    authors: Lledó B,Llácer J,Blanco L,Ortiz JA,Morales R,Fabregat A,Guerrero J,Bernabeu R

    更新日期:2019-11-01 00:00:00

  • Association of GSTM1 null polymorphism with isosorbide-5-mononitrate cardiovascular response and involvement of CGRP in healthy Chinese male volunteers.

    abstract:OBJECTIVES:To determine whether functional polymorphisms of glutathione S-transferase μ type 1 (GSTM1) and aldehyde dehydrogenase-2 (ALDH2) affect the isosorbide 5-mononitrate (IS-5-MN) response, and the role of the calcitonin gene-related peptide (CGRP) in IS-5-MN response in healthy volunteers. METHODS:A two-phase, ...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e328343ea0a

    authors: Guo R,Chen L,Li L,Guo X,Sun J,Xiong XM,Cheng ZN,Li YJ,Chen XP

    更新日期:2011-03-01 00:00:00

  • Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes.

    abstract:OBJECTIVES:Nine different functional UGT1A enzymes are generated from a single UGT1A gene by alternative splicing, with each enzyme having a unique exon 1. SN-38, the active metabolite of the anticancer agent irinotecan, is metabolized by both UGT1A1 and UGT1A9. We aim to characterize the UGT1A9-UGT1A1 haplotypes in As...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/01213011-200505000-00004

    authors: Innocenti F,Liu W,Chen P,Desai AA,Das S,Ratain MJ

    更新日期:2005-05-01 00:00:00

  • Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 genotype.

    abstract::Genotyping N-acetyltransferase 2 (NAT2) is of high relevance for individualized dosing of antituberculosis drugs and bladder cancer epidemiology. In this study we compared a recently published tagging single nucleotide polymorphism (SNP) (rs1495741) to the conventional 7-SNP genotype (G191A, C282T, T341C, C481T, G590A...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e3283493a23

    authors: Selinski S,Blaszkewicz M,Lehmann ML,Ovsiannikov D,Moormann O,Guballa C,Kress A,Truss MC,Gerullis H,Otto T,Barski D,Niegisch G,Albers P,Frees S,Brenner W,Thüroff JW,Angeli-Greaves M,Seidel T,Roth G,Dietrich H,Ebbin

    更新日期:2011-10-01 00:00:00

  • Assessing the clinical impact of CYP2C9 pharmacogenetic variation on phenytoin prescribing practice and patient response in an integrated health system.

    abstract:OBJECTIVE:To assess the impact of CYP2C9 variation on phenytoin patient response and clinician prescribing practice where genotype was unknown during treatment. METHODS:A retrospective analysis of Resource on Genetic Epidemiology Research on Adult Health and Aging cohort participants who filled a phenytoin prescriptio...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000383

    authors: Fohner AE,Ranatunga DK,Thai KK,Lawson BL,Risch N,Oni-Orisan A,Jelalian AT,Rettie AE,Liu VX,Schaefer CA

    更新日期:2019-10-01 00:00:00

  • Gene-gene interaction between DRD4 and COMT modulates clinical response to clozapine in treatment-resistant schizophrenia.

    abstract::Clozapine is the drug of choice for treatment-resistant schizophrenia. However, its use is associated with variable clinical responses and serious adverse effects. Polymorphisms in genes encoding proteins involved in synaptic neurotransmission may account for such variability. Here, we studied independent and epistati...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000314

    authors: Rajagopal VM,Rajkumar AP,Jacob KS,Jacob M

    更新日期:2018-01-01 00:00:00